European Union clinical studies have 27% rejection rate at FDA, agency calculates.
Executive Summary
EUROPEAN UNION STUDIES REVIEWED BY FDA HAVE 27% TURN-DOWN RATE, FDA Clinical Investigations Branch Chief Bette Barton, MD, told the University of Texas International Industrial Pharmacy Conference Feb. 26. FDA had inspected 95 EU studies through the end of calendar year 1995, Barton noted.